 Cyclin-Dependent Kinase Inhibitor p21
"Cyclin-Dependent Kinase Inhibitor p21" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cyclin-dependent kinase inhibitor that mediates TUMOR SUPPRESSOR PROTEIN P53-dependent CELL CYCLE arrest. p21 interacts with a range of CYCLIN-DEPENDENT KINASES and associates with PROLIFERATING CELL NUCLEAR ANTIGEN and CASPASE 3.
| Descriptor ID |
D050759
|
| MeSH Number(s) |
D12.644.360.225.500 D12.776.167.187.500 D12.776.476.225.500 D12.776.624.776.355.500
|
| Concept/Terms |
Cyclin-Dependent Kinase Inhibitor p21- Cyclin-Dependent Kinase Inhibitor p21
- Cyclin Dependent Kinase Inhibitor p21
- Cdk2 Inhibitor Protein
- CDK2-Associated Protein 20 kDa
- CDK2 Associated Protein 20 kDa
- CDKN1 Protein
- CDKN1A Protein
- Senescent Cell-Derived Inhibitor Protein 1
- Senescent Cell Derived Inhibitor Protein 1
- Cyclin Kinase Inhibitor p21
- Cyclin-Dependent Kinase Inhibitor 1A Protein
- Cyclin Dependent Kinase Inhibitor 1A Protein
- p21 Cell Cycle Regulator
- p21 Cyclin Kinase Inhibitor
- Cdk-Interacting Protein 1
- Cdk Interacting Protein 1
- Cell Cycle Regulator p21
|
Below are MeSH descriptors whose meaning is more general than "Cyclin-Dependent Kinase Inhibitor p21".
Below are MeSH descriptors whose meaning is more specific than "Cyclin-Dependent Kinase Inhibitor p21".
This graph shows the total number of publications written about "Cyclin-Dependent Kinase Inhibitor p21" by people in this website by year, and whether "Cyclin-Dependent Kinase Inhibitor p21" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 | | 1997 | 0 | 1 | 1 | | 2000 | 0 | 1 | 1 | | 2005 | 0 | 1 | 1 | | 2006 | 1 | 0 | 1 | | 2007 | 2 | 3 | 5 | | 2008 | 2 | 1 | 3 | | 2010 | 2 | 1 | 3 | | 2011 | 0 | 1 | 1 | | 2012 | 1 | 0 | 1 | | 2013 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Cyclin-Dependent Kinase Inhibitor p21" by people in Profiles.
-
Shen H, Perez RE, Davaadelger B, Maki CG. Two 4N cell-cycle arrests contribute to cisplatin-resistance. PLoS One. 2013; 8(4):e59848.
-
Garay JP, Karakas B, Abukhdeir AM, Cosgrove DP, Gustin JP, Higgins MJ, Konishi H, Konishi Y, Lauring J, Mohseni M, Wang GM, Jelovac D, Weeraratna A, Sherman Baust CA, Morin PJ, Toubaji A, Meeker A, De Marzo AM, Lewis G, Subhawong A, Argani P, Park BH. The growth response to androgen receptor signaling in ERa-negative human breast cells is dependent on p21 and mediated by MAPK activation. Breast Cancer Res. 2012 Feb 09; 14(1):R27.
-
Regan PL, Jacobs J, Wang G, Torres J, Edo R, Friedmann J, Tang XX. Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma. Int J Oncol. 2011 Jan; 38(1):105-12.
-
Shen H, Maki CG. p53 and p21(Waf1) are recruited to distinct PML-containing nuclear foci in irradiated and Nutlin-3a-treated U2OS cells. J Cell Biochem. 2010 Dec 01; 111(5):1280-90.
-
Shen H, Maki CG. Persistent p21 expression after Nutlin-3a removal is associated with senescence-like arrest in 4N cells. J Biol Chem. 2010 Jul 23; 285(30):23105-14.
-
Moran DM, Maki CG. Nutlin-3a induces cytoskeletal rearrangement and inhibits the migration and invasion capacity of p53 wild-type cancer cells. Mol Cancer Ther. 2010 Apr; 9(4):895-905.
-
Shen H, Moran DM, Maki CG. Transient nutlin-3a treatment promotes endoreduplication and the generation of therapy-resistant tetraploid cells. Cancer Res. 2008 Oct 15; 68(20):8260-8.
-
Abukhdeir AM, Park BH. P21 and p27: roles in carcinogenesis and drug resistance. Expert Rev Mol Med. 2008 Jul 01; 10:e19.
-
Moran DM, Gawlak G, Jayaprakash MS, Mayar S, Maki CG. Geldanamycin promotes premature mitotic entry and micronucleation in irradiated p53/p21 deficient colon carcinoma cells. Oncogene. 2008 Sep 18; 27(42):5567-77.
-
Abukhdeir AM, Vitolo MI, Argani P, De Marzo AM, Karakas B, Konishi H, Gustin JP, Lauring J, Garay JP, Pendleton C, Konishi Y, Blair BG, Brenner K, Garrett-Mayer E, Carraway H, Bachman KE, Park BH. Tamoxifen-stimulated growth of breast cancer due to p21 loss. Proc Natl Acad Sci U S A. 2008 Jan 08; 105(1):288-93.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|